The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Roman Perez-Soler

Abstract

Erlotinib (Tarceva) is a reversible and highly specific inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase. Phase I studies established a fixed daily oral dose of 150 mg as the recommended dose for Phase II studies. Using this dose and schedule, the response rate in a group of 57 patients with EGFR-positive non-small cell lung cancer after failure of platinum-containing chemotherapy was 12%. The median survival was 8.4 months, and the 1-year survival was 40%. Occurrence and severity of rash were correlated with an improved survival independently of performance status. Another ongoing Phase II study in 50 patients with bronchoalveolar carcinoma has shown a response rate of 26%. Results from two Phase III front-line studies in combination with chemotherapy, TALENT and TRIBUTE, have been recently reported. The addition of erlotinib did not improve response rate, time to progression, or survival. Efforts in the continued development of erlotinib should be focused on the following: (a) investigating the reasons for the lack of relationship between EGFR expression and clinical outcome; (b) the reasons for the failure of the front-line combination trials; and (c) confirming the rash/clinical outcome relationship. Pro...Continue Reading

Associated Clinical Trials

References

May 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F A ShepherdJ Berille
Jul 4, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M HidalgoE K Rowinsky
May 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ezra E W CohenEverett E Vokes

❮ Previous
Next ❯

Citations

Jan 29, 2008·Cancer Metastasis Reviews·K N SyrigosMuhammad Wasif Saif
Mar 26, 2014·Nature Reviews. Clinical Oncology·Ron H J MathijssenJaap Verweij
Nov 15, 2006·Annals of Surgical Oncology·Neeltje SteeghsHans Gelderblom
May 20, 2009·Targeted Oncology·Tianhong Li, Roman Perez-Soler
Jun 28, 2011·Expert Review of Respiratory Medicine·Mariacarmela SantarpiaRafael Rosell
Apr 12, 2013·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Yiyu ZouBilal Piperdi
May 3, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Lela E BuckinghamPhilip Bonomi
Jun 4, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Tianhong LiRoman Perez-Soler
Nov 18, 2005·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Arkadiusz Z DudekMani Keshtgarpour
Jul 1, 2005·Seminars in Oncology·Janessa J LaskinDavid H Johnson
Jul 5, 2005·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Thomas W HermannReid P Bissonnette
Jan 30, 2015·British Journal of Pharmacology·Doriano FabbroHenrik Moebitz
Oct 13, 2007·Expert Opinion on Pharmacotherapy·Cesare GridelliCiro Guerriero
Jun 15, 2005·Expert Opinion on Pharmacotherapy·Fiona H BlackhallNicholas Thatcher
Feb 8, 2008·Cellular Signalling·Feng ShenWannian Yang
Jun 13, 2015·BioMed Research International·Amelia KellarDon Morris
Aug 21, 2013·Biomaterials·Chetan YewaleAmbikanandan Misra
Aug 27, 2014·Frontiers in Oncology·Grzegorz J KorpantyNatasha B Leighl
Mar 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William Pao, Vincent A Miller
Dec 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David J Stewart, Razelle Kurzrock
Dec 3, 2009·Expert Review of Neurotherapeutics·Nikhil G Thaker, Ian F Pollack
Mar 25, 2006·Future Oncology·Tufia Haddad, Douglas Yee
Jul 9, 2005·Expert Review of Anticancer Therapy·Constantine S Mitsiades, Nicholas Mitsiades
Jul 9, 2005·The Journal of Pharmacology and Experimental Therapeutics·Amit Arora, Eric M Scholar
Aug 5, 2005·The Oncologist·Martin H CohenRichard Pazdur
Jun 20, 2018·Drugs·Asunción Díaz-SerranoLuis Paz-Ares Rodríguez
Feb 1, 2006·Personalized Medicine·Mike WhelanAngus Dalgleish
Jun 25, 2014·Oncology Letters·Jin-Sheng OuyangLi Yang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Masahiro FukuokaJose Baselga
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Giuseppe GiacconeDavid H Johnson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Roy S HerbstDavid H Johnson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Roman Perez-SolerPhilip Bonomi
© 2022 Meta ULC. All rights reserved